The Pharmaceutical Market: South Africa Opportunities and Challenges

Publisher Name :
Date: 8-Nov-2012
No. of pages: 103

OVERVIEW OF THE PHARMACEUTICAL MARKET IN SOUTH AFRICA

The government drive to support local production and reduce the country’s reliance on imports, in addition to global epidemiological and demographic trends, are all positive factors contributing to long-term growth in the pharmaceutical market. However, deep segregation between private and public healthcare facilities continues to leave the vast majority of the population without medical care. BMI believes this will be rectified through the creation of the National Health Insurance scheme over the next decade, but in the meantime unemployment, lack of education and geographical inaccessibility to healthcare for the wider population will continue to hinder growth in the market.

Headline Expenditure Projections Pharmaceuticals: ZAR27.19bn (US$3.74bn) in 2011 to ZAR29.61bn (US$3.61bn) in 2012; +8.9% in local currency and -3.5% in US dollar terms. Healthcare: ZAR261.51bn (US$36.01bn) in 2011 to ZAR285.26bn (US$34.79bn) in 2012; +9.1% in local currency terms and -3.4% in US dollar terms. Medical devices: ZAR11.43bn (US$1.57bn) in 2011 to ZAR12.19bn (US$1.49bn) in 2012; +6.7% in local currency terms and -5.5% in US dollar terms. Forecast changed due to depreciation of the South African rand.

Product Description

The South Africa Pharmaceuticals & Healthcare Report features Espicom’s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

Espicom’s South Africa Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the South Africa pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark Espicom’s independent pharmaceutical and healthcare industry forecasts to test other views – a key input for successful budgeting and strategic business planning in the South Africa pharmaceutical and healthcare market.
  • Target business opportunities and risks in the pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in South Africa.
  • Assess the activities, strategy and market position of your competitors, partners and clients via our Company Profiles (inc. SWOTs, KPIs and latest activity) and Competitive Landscape Tables.

Executive Summary & Industry SWOT

An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect Espicom’s forecast analysis, and taken together with Espicom’s political, economic and business environment SWOTS, it gives a complete overview of market climate.

Market Summary
Snapshot of key market characteristics, including total size of pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape.

Regulatory Regime
Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as an analysis of the overall regulatory burden.

Industry Developments
Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

Espicom Industry Forecasts
Forecasts to end-2016 for all key industry indicators (see list below) supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:

  • Healthcare: Total healthcare expenditure (US$bn), healthcare expenditure (% of GDP), healthcare expenditure per capita (US$), hospital beds (per `000 population), doctors (per `000 population), birth and mortality rate (per `000 population)
  • Pharmaceutical market: Drug expenditure (US$bn), drug expenditure (% of GDP), drug expenditure per capita (US$)
  • Patented drug market: Prescription drug sales (US$bn), prescription sales (% of total sales), sales broken down by 14 therapeutic areas (cardiovascular, anti-infectives etc.)
  • Generic drug market: Generic product sales (US$bn), generic sales (% of total sales)
  • OTC drug market: OTC sales (US$bn), OTC sales (% of total sales), sales broken down by product types (analgesics, skin treatments, vitamins and minerals etc.)
  • Medical Devices: Medical device sales (US$bn), medical device sales (% of total healthcare market)
  • Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt.

Competitive Landscape

The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales – for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.

Company Profiles

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of Espicom’s industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

The Pharmaceutical Market: South Africa Opportunities and Challenges

EXECUTIVE SUMMARY... 1
Snapshot: Strategic Espicom Analysis.........2
Snapshot: Key Data Projections......3

MACROENVIRONMENT . 4

POLITICAL.....4

ECONOMIC...5
Projections...........5

LEGAL............6

DEMOGRAPHIC........7
Projections...........7
Latest Figures.......8
Demographic Indicators..9
Birth Rate... 9
Death Rate. 9
Infant MortalityRate (IMR) 9
Life Expectancy at Birth.... 9

EPIDEMIOLOGY............ 10

DISEASE BURDEN...10

DISEASE PREVALENCE........11
Communicable Diseases11
HIV/AIDS... 11
Malaria...... 11
TB.. 12
Non-Communicable Diseases....12
Cancer....... 12

HEALTHCARE - ACCOMPANYING HEALTH STATISTICS.. 13

ORGANISATION......13
National Health Insurance..........13

EXPENDITURE.........14
Projections.........14
Latest Figures.....15

INFRASTRUCTURE..16
Hospital Infrastructure..16
Netcare Group ..... 17
Hospital Bed Provision...17

WORKFORCE...........18
Projections.........18
Physicians...........19
Public Workforce............19

REGULATORY AFFAIRS 20

NATIONAL AUTHORITY..... 20

MARKETING REGISTRATION.......... 20
National Procedures.......20

TRADE REGULATIONS ........21
Parallel Trade.....21

PRICING & REIMBURSEMENT... 22

NATIONAL AUTHORITY..... 22

PRICING...... 22
Dispensing Fees Charged by Pharmacists..........22

REIMBURSEMENT . 23
Essential Drugs List........23

DISTRIBUTION CHANNELS....... 24

DRUG RETAILING....24
Public Pharmacies............24
Private Pharmacies..........24
Pharmacy Trade Association......25
USAP.........25
Leading Pharmacy Chains..........25
Clicks.........25
Dischem...25
Medipost Courier Pharmacy.......25

MARKET ANALYSIS....... 26

SIZE 26
Projections.........26
Historical Figures............28
Current Structure............29
ARV Tender...........30

PRODUCT DEVELOPMENT 30

MANUFACTURING. 30

TRADE.........31
Exports..31
Imports..33
Balance of Trade38

COMPETITION.. 39

TRADE ASSOCIATION..........39

PIASA........39

COMPANY INTELLIGENCE. 40
Adcock Ingram.....40
Aspen Pharmacare...........40
Merck South Africa........... 41
Competitive Strategies..41
OTC PHARMACEUTICALS.......... 43

MARKET SIZE...........43

COMPETITION.........43
Trade Association...........43
SMASA......43

GENERIC PHARMACEUTICALS 44

MARKET SIZE.......... 44

COMPETITION........ 44
Trade Association...........44
NAPM........44
Company Intelligence....45
Aspen Pharmacare...........45
Cipla Medpro........45
Ranbaxy...45

BIOLOGICS & BIOSIMILARS......46

PRODUCT DEVELOPMENT 46
Lifelab.......46
TIA46

COMPETITION........ 46
Trade Association...........46
IMSA..........46
Company Intelligence....47
Arvir Technologies........... 47
Bioclones.. 47
Elevation Biotech. 47
iThemba Pharmaceuticals........... 47
Key Oncologics..... 47
National Bioproducts Institute... 47

CONCLUSIONS: OPPORTUNITIES & CHALLENGES.........48
Strategic Espicom Analysis............ 48
MACROENVIRONMENT...48
EPIDEMIOLOGY..48
HEALTHCARE......48
REGULATORY AFFAIRS....49
PRICING & REIMBURSEMENT......49
DISTRIBUTION CHANNELS..........50
MARKET.50
COMPETITION ....51
OTC PHARMACEUTICALS51
GENERIC PHARMACEUTICALS.....51
BIOLOGICS & BIOSIMILARS.........51
Radar Analysis........53
SWOT Analysis........53

DIRECTORY...... 54

COMPETITION........ 54
Pharmaceutical Companies........54
Generic Companies........54
Biologic Companies........54

GOVERNMENT ORGANISATIONS.. 54

PRODUCT DEVELOPMENT 54

TRADE ORGANISATIONS... 54

List of Tables
Espicom Analysis of the Pharmaceutical Market, 2012.. 2
Key Data Projections, 2011-2016.......... 3
Political Landscape, 2012........ 4
Regional Ranking of Projected Economies, 2016........... 5
Projected Economy, 2011-2016............ 5
Regional Ranking of Projected Demographics, 2016..... 7
Projected Demographics, 2011-2016... 7
Population by Gender & Province, 2011............ 8
Population by Gender & Age, 2011...... 8
Births, Deaths & Natural Increase, 1997-2010.. 9
Selected Causes of Death by Sex, 2007-2009.. 10
Estimated Number of Adults & Children Receiving ART, 2005-2010.......11
Reported Cases of Selected Communicble Diseases, 1990-201012
Regional Ranking of Projected Health Expenditure, 2016........ 14
Projected Health Expenditure, 2011-2016....... 14
Health Funding by Sector, 2007/08-2009/10 (Rand Millions)...15
Public Sector Hospitals by Province, 2004-2011........... 16
Private Sector Hospitals by Province, 2004-2010......... 16
Public Sector Hospital Beds by Province, 2005-2009....17
Private Sector Hospital Beds by Province, 1998-2010...17
Regional Ranking of Projected Physicians, 2016.......... 18
Projected Physicians, 2011-2016........ 18
Physicians by Province, 2009-2011.... 19
Public Physicians, Nurses, Dentists & Pharmacists, 2000-2011 19
Regional Ranking of Projected Pharmaceutical Markets, 2016 26
Projected Pharmaceutical Market at Retail Prices, 2011-2016.. 28
Historical Pharmaceutical Market at Retail Prices, 1995-2010. 28
Pharmaceutical Retail Sales by Month at Current Prices, 2005-2011 (R Millions) 29
Pharmaceutical Exports by Category, 1995-2010 (US$000s).... 31
Pharmaceutical Exports by Country/Region, 2010 (US$000s).. 32
Pharmaceutical Imports by Category, 1995-2010 (US$000s)... 33
Imports of Raw Materials by Country/Region, 2010 (US$000s)............ 35
Imports of Antisera & Vaccines by Country/Region, 2010 (US$000s).... 36
Imports of Medicaments by Country/Region, 2010 (US$000s) 37
Balance of Pharmaceutical Trade, 1995-2010 (US$000s)......... 38
Member Companies of PIASA, 2011... 39
Member Companies of SMASA, 2011. 43
Member Companies of NAPM, 2011..44
Member Companies of IMSA, 2011....46
Espicom Analysis of the Pharmaceutical Market, 2012 52
SWOT Analysis of the Pharmaceutical Market, 2012... 53

List of Charts
Regional Comparison of Projected Pharmaceutical Markets at Retail Prices, 2016 27
Regional Comparison of Projected Pharmaceutical Market Share, 2016........... 27
Historical Pharmaceutical Market at Retail Prices, 1995-2010. 29
Pharmaceutical Exports, 1995-2010 (US$ Millions) .... 31
Pharmaceutical Imports, 1995-2010 (US$ Millions).... 33
Pharmaceutical Imports by Country/Region, 2010 (%)............ 34
Balance of Pharmaceutical Trade, 1995-2010 (US$ Millions)... 38
Radar Graph of the Pharmaceutical Market, 2012...... 53

  • Global Stem Cell Therapy Industry Witnesses Steady Growth
    Stem cell research which is one of the most contemporary areas of biology has developed rapidly in the last couple of years. Increased funding in stem cell research by both government and private organizations is one of the main drivers in the stem cell therapy industry. Stem cells are used in various medical therapies such [...]
  • Global Lubricant Market Driven by Increased Demand in Automotive Industry
    With growth in the automobile industry, the demand for lubricants has also increased. The robust growth in manufacturing with increase in industrial production, particularly in countries such as China and India are also fueling the demand for lubricants. In 2013, the global market for lubricants had reached a value of 123.64 billion USD. By 2020, [...]
  • Global Cybersecurity Market Driven by Increase in Cyber Attacks
    In recent years, the global market for cybersecurity has grown steadily, with the rapid adoption of cloud-based services. As more and more corporate and government organizations are realizing the importance of protecting data and intellectual property, the market for cybersecurity is going to expand. In 2014, the global market for cybersecurity was valued at 95.60 [...]
  • Global Epilepsy Drug Market Continues to Grow Steadily
    The global epilepsy drug market has grown steadily in recent years with increased sales of anti-epileptic drugs which are targeted at reducing seizures. Epilepsy is a condition which affects the brain and is characterized with repeated seizures in the patient. Treatment for epilepsy usually involves the use of medicines known as anti-epileptic drugs which prevents [...]
  • Global Meat and Poultry Product Market to Witness Steady Growth
    As global demand for meat and poultry products continues to rise, the market for meat and poultry is also expected to grow steadily. The market for meat and poultry products is driven by rise in disposable income, growing awareness among consumers about the importance of adding protein to their diet, and change in eating habits. [...]
  • Graft-Versus-Host Disease (GVHD) Treatment Market worth $407 million by 2018
  • The graft-versus-host disease (GVHD) treatment market value will increase from $297 million in 2013 to $407 million by 2018, at a Compound Annual Growth Rate (CAGR) of 6.59%, according to research and consulting firm GlobalData. The company’s latest report* states …

  • Poland Pharmaceutical Industry Growing at 8.3% CAGR to 2020
  • Factors such as the growing elderly population, increasing availability of affordable medicines, and transparent regulatory guidelines will provide the necessary impetus for the growth of the Polish pharmaceutical market, but a decrease in mark-up prices and the country’s stringent drug …

  • Asia-Pacific, Led by China, Drive the Global Methanol Industry
  • China is driving the global methanol industry, with tremendous demand from both its energy and petrochemicals sectors. It accounts for 87.9% of Asia-Pacific’s (APAC) methanol capacity, and 51.9% of the global methanol capacity. Despite a large planned capacity increase in …

  • Diagnostic X-ray Imaging Market worth $4.0 billion by 2020
  • GlobalData estimates that the global diagnostic X-ray imaging market, worth $2.4 billion in 2012, will reach almost $4.0 billion by 2020, increasing at a Compound Annual Growth Rate (CAGR) of 6.7% during the forecast period. Many players are active in …

  • Graft-Versus-Host Disease Market Forecast to 2023
  • Graft-versus-host disease (GVHD) is a common complication of allogeneic hematopoietic stem cell transplantation (HSCT) that occurs when the donated (graft) cells are rejected and attack the host’s cells as foreign. GVHD can progress from mild to severe forms as either …

  • Anthrax Global Clinical Trials Review, H2, 2014
    Published: 21-Nov-2014        Price: US $2500 Onwards        Pages: 79
    GlobalData's clinical trial report, "Anthrax Global Clinical Trials Review, H2, 2014" provides data on the Anthrax clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Anthrax. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also ......
  • Chagas Disease (American Trypanosomiasis) Global Clinical Trials Review, H2, 2014
    Published: 21-Nov-2014        Price: US $2500 Onwards        Pages: 65
    GlobalData's clinical trial report, "Chagas Disease (American Trypanosomiasis) Global Clinical Trials Review, H2, 2014" provides data on the Chagas Disease (American Trypanosomiasis) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Chagas Disease (American Trypanosomiasis). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary ......
  • Bacterial Vaginosis Global Clinical Trials Review, H2, 2014
    Published: 21-Nov-2014        Price: US $2500 Onwards        Pages: 79
    GlobalData's clinical trial report, "Bacterial Vaginosis Global Clinical Trials Review, H2, 2014" provides data on the Bacterial Vaginosis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Bacterial Vaginosis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, ......
  • Bacterial Pneumonia Global Clinical Trials Review, H2, 2014
    Published: 21-Nov-2014        Price: US $2500 Onwards        Pages: 146
    GlobalData's clinical trial report, "Bacterial Pneumonia Global Clinical Trials Review, H2, 2014" provides data on the Bacterial Pneumonia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Bacterial Pneumonia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, ......
  • Aspergillosis Global Clinical Trials Review, H2, 2014
    Published: 21-Nov-2014        Price: US $2500 Onwards        Pages: 125
    GlobalData's clinical trial report, "Aspergillosis Global Clinical Trials Review, H2, 2014" provides data on the Aspergillosis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Aspergillosis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the ......
  • Cryptococcal Meningitis Global Clinical Trials Review, H2, 2014
    Published: 21-Nov-2014        Price: US $2500 Onwards        Pages: 79
    GlobalData's clinical trial report, "Cryptococcal Meningitis Global Clinical Trials Review, H2, 2014" provides data on the Cryptococcal Meningitis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Cryptococcal Meningitis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, tr......
  • Cerebral (Fatal) Malaria Global Clinical Trials Review, H2, 2014
    Published: 21-Nov-2014        Price: US $2500 Onwards        Pages: 64
    GlobalData's clinical trial report, "Cerebral (Fatal) Malaria Global Clinical Trials Review, H2, 2014" provides data on the Cerebral (Fatal) Malaria clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Cerebral (Fatal) Malaria. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase,......
  • African Trypanosomiasis Global Clinical Trials Review, H2, 2014
    Published: 21-Nov-2014        Price: US $2500 Onwards        Pages: 48
    GlobalData's clinical trial report, "African Trypanosomiasis Global Clinical Trials Review, H2, 2014" provides data on the African Trypanosomiasis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on African Trypanosomiasis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, tr......
  • Cryptosporidiosis Global Clinical Trials Review, H2, 2014
    Published: 21-Nov-2014        Price: US $2500 Onwards        Pages: 58
    GlobalData's clinical trial report, "Cryptosporidiosis Global Clinical Trials Review, H2, 2014" provides data on the Cryptosporidiosis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Cryptosporidiosis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, promin......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs